The American Diabetes Association faces mounting internal turbulence after leaders reportedly blocked journal editors from publishing on recent controversies at its annual conference.
The American Diabetes Association faces mounting internal turbulence after leaders reportedly blocked journal editors from publishing on recent controversies at its annual conference.
READ MORE
The FDA has approved Merck’s once-daily pill, making it the first oral PCSK9 inhibitor available for patients with high cholesterol.
CMS’s proposed 2027 Physician Fee Schedule includes sweeping changes to remote patient monitoring: specifically, a plan to bar Medicare payment for services provided by third-party vendors, spurred by recent fraud findings. Stakeholders now confront big questions on the future of digital chronic care management.
Healthcare organizations are widely praising the unanimous passage of a major bill to reform Medicare Advantage prior authorization requirements by a House Committee. This legislative milestone reflects growing bipartisan support for overhauling processes long criticized by patients, physicians, and insurers alike.
A key vote in the U.S. Senate has blocked efforts to end the Trump administration’s pilot program using artificial intelligence for Medicare prior authorization. The news highlights persistent policy divides regarding technology’s role in healthcare cost control and patient care.
The FDA’s first current Good Manufacturing Practice (cGMP) warning letter referencing AI-generated work highlights new scrutiny for life sciences manufacturers. Experts suggest that human oversight and robust quality controls are still paramount as industry adapts AI technologies.
Eli Lilly has announced the acquisition of AtaiBeckley, a biopharma company focused on psychedelic compounds for depression, marking a substantial investment in the expanding neuroscience sector.
The first half of 2026 is seeing a surge in biopharma IPO activity, with companies like Braveheart Bio, Attovia Therapeutics, and Vogenx plotting competitive paths in cardiometabolic and immunology markets.
Pfizer has dropped another antibody-drug conjugate (ADC) for solid tumors from its pipeline, just weeks after a late-stage failure in non-small cell lung cancer. The move underscores ongoing challenges in ADC development and the broader landscape for novel cancer therapeutics.
The recent death of a high-profile figure from aortic dissection highlights ongoing gaps in awareness, risk prediction, and prevention of this rare but deadly disorder. We analyze the current landscape and potential future measures for improving patient outcomes.
Celcuity’s intravenously infused Revtorpyk has gained FDA approval for advanced breast cancer, representing the first in a novel class targeting a key cancer-associated pathway.
